The outcome of patients with higher-risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low-dose clofarabine and cytarabine for these patients. METHODS: Seventy patients with higher-risk MDS who had no response, progressed, or relapsed after at least 4 cycles of HMA therapy were treated. RESULTS: The median age was 72 years. Thirty-nine percent of the patients had high-risk disease according to the International Prognostic Scoring System, and 50% of the patients had poor-risk cytogenetics. Twenty-three percent of the patients had therapy-related MDS. The median number of prior cycles of HMA was 6 (range, 4-45). The overall response rate was 44%. The 6-week mortality rate was 9%. Grade 3 and higher nonhematologic toxicities were rare, but infections occurred in 52% of the patients, and fever of unknown origin occurred in 33%. The median overall survival (OS) was 10 months (95% confidence interval, 1-37 months). Thirteen percent of the patients underwent allogeneic stem cell transplantation. The responding patients had a median OS of 22 months, whereas the nonresponding patients had a median OS of 4 months. A complex karyotype was associated with worse response rates and OS. CONCLUSIONS: The combination of low-dose clofarabine and cytarabine is clinically active in these patients with few treatment options. Cancer 2017;123:629-37.
INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by bone marrow failure, evidence of dysplastic marrow, and a relatively high rate of transformation into acute myeloid leukemia (AML). 1, 2 The standard frontline therapy for most patients with MDS is a hypomethylating agent (HMA) such as azacitidine or decitabine. 3, 4 Despite the significant clinical activity of these agents, a large majority of patients will either not respond to HMA or lose their response to therapy. The median survival for these patients with so-called HMA failure is less than 4 to 6 months; their 1-year survival probability is less than 30%. 5, 6 No approved therapeutic alternatives currently exist for this group of patients; therefore, there is an urgent need to develop new agents for patients with HMA failure.
Clofarabine is a second-generation nucleoside analogue that is similar in molecular structure to fludarabine and cladribine but has distinct features that expand its spectrum of activity. 7 Besides its ability to effectively inhibit DNA synthesis, it also causes disruption of mitochondrial membrane integrity with a resultant release of proapoptotic proteins, and it is an effective inhibitor of ribonucleotide reductase. The latter leads to intracellular depletion of natural nucleosides and thus enhanced uptake of the analogue during DNA synthesis. Furthermore, clofarabine has a higher affinity to deoxycytidine kinase, the rate-limiting enzyme in intracellular nucleoside phosphorylation, and is converted to a triphosphate metabolite that has a longer retention time than those of its predecessors.
HMA failure. [8] [9] [10] Furthermore, we previously reported that an oral formulation of clofarabine at doses between 20 and 40 mg/m 2 daily for 5 days resulted in an ORR of 43% (with a 25% complete remission [CR] rate); this included a 30% response rate (10% CR rate) among patients for whom HMA therapy failed. 11 In that study, patients who received lower doses of clofarabine were less likely to experience serious infectious complications and showed similar response profiles. We subsequently confirmed that lower doses of clofarabine (15 mg/m 2 have comparable clinical activity with better safety profiles. 12 Similarly, we have reported on the feasibility and efficacy of a combination of lower doses of clofarabine with lowdose cytarabine in patients with high-risk MDS and AML, and the combination was more active than singleagent clofarabine. 13 The aim of this phase 2 study was to evaluate the safety and efficacy of the combination of lower dose clofarabine and cytarabine in a larger cohort of patients with higher-risk MDS after HMA failure on the basis of the ORR, overall survival (OS), and response duration.
MATERIALS AND METHODS

Patients
From January 2012 to February 2015, 70 eligible patients were enrolled in this prospective study (NCT01444742), which was conducted according to the guidelines of The University of Texas MD Anderson Cancer Center and approved by the Institutional Review Board. Adult patients with refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia, or International Prognosis Scoring System (IPSS) scores 2 of intermediate 1 or higher for whom prior HMA therapy had failed were eligible. A failure to respond to prior HMA was defined as progression while the patient was receiving HMA, a loss of response, or a lack of response after at least 4 cycles of either decitabine or azacitidine. 6 Furthermore, patients had to have an Eastern Cooperative Oncology Group performance status of 2 or less and have adequate organ function (ie, bilirubin level 1.5 mg/dL, aspartate aminotransferase/alanine aminotransferase level < 3 times the upper limit of normal, and creatinine level 2 mg/dL).
Treatment Plan and Follow-Up
Induction therapy consisted of intravenous clofarabine at a dose of 10 to 15 mg/m 2 daily for 5 days and subcutaneous cytarabine at a dose of 20 mg twice daily for 7 days. Up to a maximum of 3 cycles of induction therapy could be administered for nonresponding patients; beyond that, nonresponding patients were to be taken off the study. Responding patients could proceed with consolidation at the same dose of clofarabine and cytarabine twice daily for 3 and 5 days, respectively. Responding patients could receive up to 12 cycles of consolidation. Cycles were repeated every 4 to 8 weeks; this depended on the resolution of toxicities and peripheral blood counts. Bone marrow aspiration, biopsy, or both were performed at the end of course 1. If a patient was not in remission at this point, further bone marrow aspiration and/or biopsy could be scheduled at the investigator's discretion or on the basis of the patient's peripheral blood counts. After the completion of therapy, patients were followed with complete blood counts every 1 to 2 months and with blood chemistry profiles every 6 6 2 months.
Response Criteria and Statistical Analysis
Responses were coded according to the modified 2006 International Working Group criteria.
14 Differences among variables were evaluated with the chi-square test and the Mann-Whitney U test for categorical and continuous variables, respectively. Event-free survival (EFS) was defined as the time interval between the start of therapy and the date of a lack of response, a loss of response, transformation, or death, whichever occurred first. Response duration was defined from the date of response to the date of relapse. OS was defined as the time between the start of therapy and death. Patients who were alive were censored at the last follow-up date. Survival probabilities were calculated with the Kaplan-Meier method and were assessed from the time of therapy initiation; they were compared with the log-rank test. The CR rate, OS, and toxicity were monitored during the study, and all data were used to update the prior distributions for toxicity and efficacy parameters. 15 The study was to be stopped if at any point there was less than a 1% chance that the CR rate would be more than 20%, there was less than a 5% chance that the median OS would be 6 months or more, or there was more than a 95% chance that the study drug-related grade 3 toxicity rate would be more than 30%. Univariate and multivariate analyses were performed to identify potential prognostic factors associated with the overall response to therapy and OS. For multivariate analyses, we used a logistic regression model for response and a Cox proportional hazards model for OS. A P value < .05 (2-tailed) was considered statistically significant. [16] [17] [18] Gene Sequencing
We performed a mutation analysis with a 28-gene panel as previously described. [19] [20] [21] Briefly, genomic DNA was 
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1 . The median age was 72 years; 93% of the patients were 60 years old. The median bone marrow blast percentage was 15%, and 85% and 82% of the enrolled patients had higher-risk disease according to the IPSS and revised IPSS, respectively. 22 Twenty-four percent of the patients had poor-risk cytogenetics, including chromosome 5 and 7 abnormalities and a complex karyotype. Sixteen patients (23%) had therapy-related MDS.
Seventy-one percent of the patients had received azacitidine, 17% had received decitabine, and 11% had received both HMAs. More than half of the patients (56%) had a previous response to HMA, and 31 patients (44%) had primary refractory disease. 6 Patients received a median of 6 cycles of HMA (range, 4-31).
Molecular Alterations
A mutation analysis was performed for 57 patients (81%) with a 28-gene next-generation sequencing panel. Thirtyfive patients (61%) had at least 1 mutation, and 9 patients (16%) had 2 mutations or more. The most common mutations were RAS (19%), IDH2 (16%), and TP53 (7%). Of the 26 patients with a diploid karyotype, 14 (54%) had identifiable molecular alterations. Cytogenetic abnormalities and molecular mutations are summarized in Figure 1 .
Response to Therapy
All 70 patients were evaluable for their response ( Table 2) . The ORR was 44%, with the best response being CR in 19% of the patients, marrow CR in 21%, a partial response (PR) in 1%, and hematologic improvement (HI) in 3%. The median time to response was 43 days (range, 9-191 days). The best response was achieved after a median of 2 cycles (range, 1-7 cycles), and the median duration of response was 9 months (95% confidence interval [CI], 7-11 months). Early mortality (defined as death within 6 weeks) occurred in 6 patients (9%).
We used univariate and multivariate analyses to identify factors associated with response. According to the univariate analysis, leukopenia and a complex karyotype (defined as at least 3 chromosomal abnormalities) were associated with a lower likelihood of response (Tables 3 and 4) . Unlike the IPSS classification (P 5 .054), the revised IPSS had a significant impact on predicting responses (P 5 .015). According to the multivariate analysis, a complex karyotype was the only independent factor predicting a response, and patients with complex karyotypes had a lower likelihood of response (odds ratio, 0.15; 95% CI, 0.03-0.71; P 5 .02). Out of 33 patients with a diploid karyotype, 21 (64%) responded (5 with CR, 4 with CR with incomplete platelet recovery, 2 with HI, 9 with marrow CR, and 1 with partial response), and the median response duration was 6.9 months. A previous response to HMA was not associated with a response to subsequent therapy with clofarabine. There was no difference in the responses before and after the modification of the protocol's dosing schedule (P 5 .488).
Survival
With a median follow-up of 17 months (range, 1-37 months), the 1-year response rate and the EFS and OS rates were 23%, 4%, and 42%, respectively ( Fig. 2A-C) . The median EFS and OS times were 3 (95% CI, 2-4 months) and 10 months (95% CI, 1-37 months), respectively. The median OS for responding and nonresponding patients was 22 (95% CI, 10-37 months) and 4 months (95% CI, 1-5 months), respectively (Fig. 2D) . Although a major improvement in survival was observed in patients achieving CR (n 5 13), marrow CR/PR/HI patients (n 5 18) also had a survival improvement in comparison with nonresponding patients. The median OS for CR patients, marrow CR/PR/HI patients, and nonresponding patients was 22 (95% CI, 14-30 months), 15 (95% CI, 10-29 months), and 4 months (95% CI, 5-16 months), respectively.
There was no difference in OS whether patients were censored or not censored at the time of allogeneic stem cell transplantation (ASCT). Twenty-eight cases (40%) transformed into AML within a median of 2 months (range, 1-25 months). At the last follow-up, 26 patients (37%) remained alive: 2 were still receiving lowdose clofarabine and cytarabine, 5 were alive in response after ASCT, 15 were receiving salvage therapy, 1 had completed the 12 courses of consolidation and was being monitored, 1 went to hospice, and 2 were lost to followup. Overall, 3 patients were long-term responders and did not undergo ASCT: 1 completed therapy, and 2 were still receiving their consolidations (7 and 9 cycles, respectively). According to the univariate analysis, both scoring systems (IPSS and revised IPSS) were predictive for survival. However, in the multivariate analysis, a complex karyotype, a platelet count < 30 3 10 9 /L, and a poor performance status were independently associated with poor survival (Tables 3 and 4 ). In addition, the response to the combination of low-dose clofarabine and cytarabine was independently associated with better OS (hazard ratio, 0.16; 95% CI, 0.08-0.34; P < .001; Fig. 2D) . A previous response to HMA did not affect the outcomes for these patients. The median survival for patients with and without complex karyotypes was 3.2 and 14.6 months, respectively (Fig. 2E ). For patients with diploid karyotypes, the median OS was 14.9 months (95% CI, 8.5-21.3 months) with a 1-year OS rate of 53%. The median EFS for diploid patients was 3.9 months (95% CI, 2.9-4.7 months), and the 1-year EFS rate was 8%.
ASCT
Nine of the responding patients subsequently underwent ASCT. Their median age was 64 years (range, 32-78 years). Their median time to failure on prior HMA therapy was 12 months (range, 4-24 months), and they received a median of 2 cycles (range, 1-5 cycles) of low-dose clofarabine and cytarabine. Their best responses at the time of transplantation were CR (5 patients) and bone marrow CR (4 patients). Five patients received matchunrelated transplants, 2 patients received match-related transplants, and 2 patients received cord blood transplants. The conditioning regimens included a combination of fludarabine and melphalan in 4 patients, fludarabine and busulfan in 3, and fludarabine, busulfan, and clofarabine in 2. With a median follow-up of 26 Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OR, odds ratio; PS, performance status.
Stepwise variable selection was applied separately for the analyses of response and survival. For response, only 1 variable (complex cytogenetics) met the selection criterion (P <.05).
months, 5 transplant patients remained alive: 4 were in CR, and 1 was alive with disease and was receiving salvage therapy. Four patients died after ASCT from transplantrelated complications: 3 patients experienced sepsis and multiorgan failure, and 1 patient experienced graftversus-host disease complications. The median OS for the 9 patients who underwent ASCT was 20 months (range, 6 to 41 months).
Safety
The most common side effects were grade 1 to 2 (Table  5) . Grade 3 and higher nonhematologic toxicities were rare. However, infections occurred during induction and consolidation in 36 patients (52%), and fever of unknown origin was reported in 23 patients (33%). Three patients (4%) had renal dysfunction, although each of these patients had related circumstances that included infections, sepsis, and the use of nephrotoxic agents. After 47 patients had been enrolled and several patients had experienced myelosuppressive episodes (infections during induction and prolonged thrombocytopenia), the protocol was amended to reduce the dose of clofarabine to 10 mg/m 2 /d for 5 and 3 days during the induction and consolidation phases, respectively.
Overall, patients received a median of 2 cycles, with the responding patients receiving up to 12 cycles. Dose reductions after a median of 1 course became necessary in 34% of the patients receiving clofarabine at 15 mg/m 2 and after a median of 2 courses in 13% of those receiving the lower dose schedule. This was mostly due to myelosuppression and infectious complications in the preceding courses.
Response and Outcome by Mutation Profile
There was no correlation between outcome and mutations in any of the 28 genes analyzed by next-generation sequencing. However, we note that all 4 patients with somatic TP53 mutations had a complex karyotype, and none of them responded to treatment. Conversely, in patients with a diploid karyotype, IDH1 and IDH2 mutations were the most common somatic mutations (7 patients), and 5 of these 7 patients responded (Fig. 2) .
DISCUSSION
This study indicates that the combination of low-dose clofarabine and cytarabine has clinical activity in higher-risk MDS patients after HMA failure. The ORR in this study was 44%, and the median OS was 10 months. The treatment combination was generally tolerable but was associated with relatively high rates of fever and infections that required significant supportive care.
Although therapy for patients with MDS has improved substantially over the past few years, the prognosis for patients with higher-risk disease remains poor, and this prognosis becomes even more dismal in patients who have failed to respond or have relapsed on HMA therapy. 5, 6 We and others have reported a median survival of 4 to 6 months for these patients with an estimated 12-month survival rate of 28%. No approved therapeutic alternatives currently exist for these patients, and their management is very challenging. Most current management strategies rely on supportive care or therapies normally used to treat AML, and neither is optimal for these patients. Some newer therapeutic agents such as the multikinase inhibitor rigosertib have shown promising results, but these require confirmation in larger trials. 23 Furthermore, because the mechanisms of MDS pathogenesis are not fully known, it is difficult to identify potentially effective therapeutic combinations.
Our findings are superior to our previous findings from studies using higher doses of clofarabine and highdose cytarabine regimens in patients with AML and higher-risk MDS after HMA failure, in which we reported ORRs of 29% and 26%, respectively, and 4-to 8-week mortality rates of 10% to 20%. 12, 24 Therefore, the lowdose version of this combination is potentially more active and safer in this population of patients, who often present with multiple comorbidities. However, these differences may also be related to confounding factors such as patient selection.
This study showed potentially improved outcomes in patients with either primary or secondary HMA failure and particularly in patients with a diploid karyotype. These findings contrast with those recently reported for the ONTIME phase 3 randomized trial, in which the multikinase inhibitor rigosertib was compared with best supportive care in patients with higher-risk MDS after HMA failure with OS times of 8.3 and 5.3 months, respectively. 25 Rigosertib showed a significant survival improvement only for patients with primary failure and a poor karyotype. The reasons for these differences in outcome remain unclear, but they may be related to the molecular and cellular mechanisms associated with HMA failure. Therefore, a better understanding of the mechanisms of resistance to HMA is important to better design salvage approaches and understand these disparate results.
We note that a relatively large number of our patients proceeded to ASCT. ASCT remains the only currently available curative approach for patients with higher-risk MDS. 26, 27 However, outcomes depend on the tumor burden at the time of ASCT: patients with minimal disease have better long-term outcomes and minimal relapse rates. 13 In our study, 30% of the responders were able to proceed to ASCT, with some of them achieving a long-lasting remission. Therefore, this combination could serve as a bridge to potentially curative ASCT for patients who achieve an objective response.
In conclusion, the combination of low-dose clofarabine and cytarabine in patients with higher-risk MDS after HMA failure resulted in an ORR of 44% and a median OS of 10 months, and it may be particularly effective in patients with diploid karyotypes. Our results also indicate that the combination of low-dose clofarabine and cytarabine may be useful as a bridge to ASCT in eligible patients. Although the findings of this study must be validated in a larger cohort of patients, this trial and others suggest that there may be a clinical rationale for the selection of second-line treatments based on cytogenetics at the time of HMA failure. 
